Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 3

2(33.3%)

6Total

N/A(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01217463Phase 3Completed

The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study

Role: lead

NCT01217476Phase 3Completed

The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study

Role: lead

NCT00678171Not ApplicableCompleted

A Pilot Study to Evaluate an Osteogenic Protein 1 (OP-1) Putty Spinal System and an Autograft Spinal System

Role: lead

NCT00679328Not ApplicableCompleted

OP Device vs. Bone Autograft for the Treatment of Tibial Nonunions

Role: lead

NCT00677950Not ApplicableCompleted

OP-1 Putty for Posterolateral Fusions

Role: lead

NCT00678353Completed

Study of OP-1 Putty in Uninstrumented Posterolateral Fusions

Role: lead

NCT00679107Not ApplicableCompleted

A Prospective Pilot Study of the OP-1 Putty in Uninstrumented Posterolateral Fusions

Role: lead

All 7 trials loaded